Posts

X-linked hypophosphatemia Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets. DelveInsight's  " X Linked Hypophosphatemia Market Insights, Epidemiology, and Market Forecast-2030"  report delivers an in-depth understanding of the X Linked Hypophosphatemia, historical and forecasted epidemiology as well as the X Linked Hypophosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of X Linked Hypophosphatemia Market Report are: ·   ...

Chronic Cutaneous Ulcer Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

Chronic Cutaneous Ulcers are wounds that do not heal through an orderly and timely reparation, which in turn, hinders the production of anatomic and functional integrity. This can also be re-defined as “interruption on the continuity of the body's tissue that requires a prolonged time to heal, does not heal, or recurs.” DelveInsight's  " Chronic Cutaneous Ulcer Market Insights, Epidemiology, and Market Forecast-2030"  report delivers an in-depth understanding of the Chronic Cutaneous Ulcer, historical and forecasted epidemiology as well as the Chronic Cutaneous Ulcer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Chronic Ulcers are mainly caused by conditions that slow or stop the healing process, such as inadequate blood supply or low oxygen, an infection, weak immune system, swelling in the tissues around the wound. These are mainly classified as vascular ulcers (e.g., venous and arterial ulcers), diabeti...

Nonalcoholic Steatohepatitis (NASH) Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms. DelveInsight's " Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2030"  ...

22q11.2 Deletion Syndrome Market Size in the 7MM is expected to sour at a CAGR of 41.9% during the forecast period (2021–2030) | DelveInsight

DelveInsight's  " 22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2030"  report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of 22q11.2 Deletion Syndrome Market are: In 2020, the total prevalent cases of 22q11.2 deletion syndrome were 196,476 in the 7MM. The United States , in the same year, accounted for 83,326 cases, the highest prevalence of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020. Among the EU-5 countries, the highest number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain in 2020. 22q11.2 deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary fr...